Skip to content

Clinical Study of Effectiveness of Radiotherapy Before Surgery in High-risk Relapse Hepatocellular Cancer Patients

Effectiveness of Radiotherapy Before Surgery in Patients With High-risk Relapse Hepatocellular Carcinoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02580929
Enrollment
50
Registered
2015-10-20
Start date
2014-10-31
Completion date
2017-07-31
Last updated
2015-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Hepatocellular

Keywords

Radiotherapy, General Surgery

Brief summary

This study aims to evaluate the effectiveness of radiotherapy before surgery in high-risk relapse hepatocellular cancer patients.

Interventions

RADIATIONradiotherapy

radiotherapy before surgery

Sponsors

Beijing Hope Run
CollaboratorOTHER
Peking Union Medical College
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of HCC 2. In high risk of recurrence of HCC but still can endure palliative resection 3. KPS scores are \>90 4. With Child-Pugh Class A liver funcion, serum bilirubin\< 1.5\*normal maxism; ALT and AST\< 1.5\*normal maxism; normal creatinine and urea nitrogen; WBC\>4×109/L, Hb\>110g/L, PLT\>90X109/L. 5. Have signed informed consent

Exclusion criteria

1. HCC cannot be operated 2. With Child-Pugh Class B/C 3. Have other organ cancer, excluding curative non-melanotic skin cancer and carcinoma in situ of cervix 4. Have other severe disease 5. With active hepatitis 6. Have accepted local radiation therapy in other hospitals 7. KPS scores≤70 8. Tumor edges cannot be defined 9. Have severe cirrhosis complication 10. Intensity modulated radiation therapy cannot reach required dose 11. Cannot cooperate 12. Lactant or pregnant 13. Cannnot be informed

Design outcomes

Primary

MeasureTime frame
mortality5 years

Countries

China

Contacts

Primary ContactFAN WU
wufan1011@126.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026